...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Neurosurgical focus >In vivo visualization of GL261-luc2 mouse glioma cells by use of Alexa Fluor–labeled TRP-2 antibodies
【24h】

In vivo visualization of GL261-luc2 mouse glioma cells by use of Alexa Fluor–labeled TRP-2 antibodies

机译：使用Alexa Fluor标记的TRP-2抗体在体内可视化GL261-luc2小鼠神经胶质瘤细胞

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Object For patients with glioblastoma multiforme, median survival time is approximately 14 months. Longer progression-free and overall survival times correlate with gross-total resection of tumor. The ability to identify tumor cells intraoperatively could result in an increased percentage of tumor resected and thus increased patient survival times. Available labeling methods rely on metabolic activity of tumor cells; thus, they are more robust in high-grade tumors, and their utility in low-grade tumors and metastatic tumors is not clear. The authors demonstrate intraoperative identification of tumor cells by using labeled tumor-specific antibodies. Methods GL261 mouse glioma cells exhibit high expression of a membrane-bound protein called second tyrosinase-related protein (TRP-2). The authors used these cells to establish an intracranial, immunocompetent model of malignant glioma. Antibodies to TRP-2 were labeled by using Alexa Fluor 488 fluorescent dye and injected into the tail vein of albino C57BL/6 mice. After 24 hours, a craniotomy was performed and the tissue was examined in vivo by using an Optiscan 5.1 handheld portable confocal fiber-optic microscope. Tissue was examined ex vivo by using a Pascal 5 scanning confocal microscope. Results Labeled tumor cells were visible in vivo and ex vivo under the respective microscopes. Conclusions Fluorescently labeled tumor-specific antibodies are capable of binding and identifying tumor cells in vivo, accurately and specifically. The development of labeled markers for the identification of brain tumors will facilitate the use of intraoperative fluorescence microscopy as a tool for increasing the extent of resection of a broad variety of intracranial tumors.
机译：目的对于多形性胶质母细胞瘤患者，中位生存时间约为14个月。更长的无进展生存期和总生存期与肿瘤的总切除率相关。术中识别肿瘤细胞的能力可能导致切除肿瘤的百分比增加，从而延长患者的生存时间。可用的标记方法取决于肿瘤细胞的代谢活性。因此，它们在高级别肿瘤中更健壮，在低级别肿瘤和转移性肿瘤中的用途尚不清楚。作者证明了使用标记的肿瘤特异性抗体进行术中肿瘤细胞鉴定。方法GL261小鼠神经胶质瘤细胞高表达一种称为第二酪氨酸酶相关蛋白（TRP-2）的膜结合蛋白。作者利用这些细胞建立了一种颅内免疫活性恶性神经胶质瘤模型。通过使用Alexa Fluor 488荧光染料标记针对TRP-2的抗体，并将其注射到白化病C57BL / 6小鼠的尾静脉中。 24小时后，进行开颅手术，并使用Optiscan 5.1手持式便携式共聚焦光纤显微镜在体内检查组织。通过使用Pascal 5扫描共聚焦显微镜离体检查组织。结果标记的肿瘤细胞在各自的显微镜下在体内和离体可见。结论荧光标记的肿瘤特异性抗体能够在体内，准确和特异性地结合和鉴定肿瘤细胞。用于鉴定脑肿瘤的标记物的发展将促进术中荧光显微术作为增加各种颅内肿瘤切除范围的工具的使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号